Groupe Oncologie Radiotherapie Tete Cou — Sponsor Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

2 Recruiting

8 Completed trials

5 Countries active

16 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 6 Phase II: 5 Phase I (Other): 1

Oversight events:

3 temporary halts 1 urgent safety measure 1 unexpected event across 3 trials

View oversight register →

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Squamous cell carcinoma of head and neck 3 Adenoid cystic carcinoma 1 Head and neck cancer 1

Top IMPs

CISPLATIN 6 CETUXIMAB 3 AVELUMAB 2 DOCETAXEL 2 FLUOROURACIL 2 NIVOLUMAB 2 BECOTATUG VEDOTIN 1 CARBOPLATIN 1 DURVALUMAB 1 FICERAFUSP ALFA 1 IVONESCIMAB 1 LIGUFALIMAB 1

All trials

12 total

Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma w… Pending

2025-521437-88-00 Phase II 1 country FICERAFUSP ALFA; NIVOLUMAB
Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and… Recruiting

2025-522996-27-00 Phase III 3 countries IVONESCIMAB; LIGUFALIMAB; PEMBROLIZUMAB
Clinical trial comparing induction treatment with EGFR-ADC MRG003 alone or in combination with the anti PD1 Pucotenlimab, followed by radioc… Recruiting

2023-510558-18-00 Phase II 1 country BECOTATUG VEDOTIN; PUCOTENLIMAB
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 Phase III 5 countries CISPLATIN; NIVOLUMAB
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Phase III 1 country AVELUMAB; CETUXIMAB; CISPLATIN
Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Ended

2024-513972-16-00 Phase III 2 countries CISPLATIN
Phase III trial of laryngeal preservation comparating chemotherapy followed by radiotherapy to chemotherapy administrated during radiotherap… Ended

2024-513976-16-00 Phase III 1 country CISPLATIN; DOCETAXEL; FLUOROURACIL
Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma… Halted

2023-510559-41-00 Phase II 1 country AVELUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; PACLITAXEL
Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien… Ended

2022-502584-38-00 Phase III 1 country CETUXIMAB; XEVINAPANT
Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic C… Ended

2023-503270-20-00 Phase I (Other) 1 country
Randomized trial evaluating adapted chemotherapy in patients with squamous carcinoma Ended

2024-512456-38-00 Phase II 1 country CISPLATIN; DOCETAXEL; FLUOROURACIL
Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513977-31-00 Phase II 1 country DURVALUMAB

Showing 1–12 of 12 trials

← All sponsors A–Z